Last edition
News about "AACR Annual Meeting 2026"
Nuvation Bio Secures FDA Nod for IBTROZI sNDA in ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio secures US Food and Drug Administration (FDA) acceptance of IBTROZI (taletrectinib) sNDA for ROS1-positive Non-Small Cell Lung Cancer (NSCLC), with updated response data and a target action date of January 4, 2027.
AACR Annual Meeting 2026 | 07/05/2026 | By News Bureau
Discovery Life Sciences and Mindpeak Partner for AI Cancer Biomarker Testing
Discovery Life Sciences and Mindpeak partner to bring AI-driven cancer biomarker testing in global clinical trials, aiming to reduce variability in biomarker interpretation and improve accuracy in drug development.
AACR Annual Meeting 2026 | 25/03/2026 | By News Bureau | 106
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy